Diabetic Macular Edema / Diabetic Retinopathy | Disease Landscape & Forecast | G7 | 2022

Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. The standards of care for DME include the anti-VEGFs Eylea, Lucentis, and off-label Avastin. Other approved agents for this indication are the long-acting corticosteroid implants Ozurdex and Iluvien and the anti-VEGF / Ang-2 bispecific antibody Vabysmo; Beovu—marketed for treating wet age-related macular degeneration (AMD)—also got a label expansion and became the latest anti-VEGF approved for DME. Of note, Lucentis 0.3 mg and Eylea are also approved for DR without DME in the United States, whereas Lucentis 0.5 mg is approved for DR in Europe. Competition will increase in the DR / DME market with not only the launch of ranibizumab (Lucentis) and aflibercept (Eylea) biosimilars but also the potential approval of key emerging therapies such as Roche’s ranibizumab port delivery system (Susvimo, launched in the United States in November 2021 for wet AMD) and Kodiak Sciences’ KSI-301, promising longer dosing intervals.


  • How large is the treatable DR / DME population, and how will diagnosis / drug-treatment rates change over time?
  • Do KOLs perceive any differences between Avastin, Eylea, and Lucentis? How is the use of these drugs expected to change over the next 10 years as emerging therapies enter the market? How are Iluvien and Ozurdex being used to treat DME?
  • How will Vabysmo and emerging therapies such as Roche’s ranibizumab port delivery system capitalize on the need for therapies with longer dosing schedules than those currently available in the market?
  • How will market dynamics be impacted by the launch of biosimilars of Lucentis 0.5 mg and Eylea?
  • How have Lucentis and Eylea been incorporated into the treatment algorithm for DR exclusive of DME in the United States? What would be the impact of Novartis’s Beovu if it is successfully launched for PDR?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.


Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with thought-leading retinal specialists and supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of severe NPDR, PDR, and DME, by country, including diagnosed / drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key DR and DME therapies through 2031, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase III / PR: 4 drugs; Phase II: 10 drugs.

Login to access report